News

News 08.11.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of data pertaining to two programs, including...

News 05.11.2024 Zurich, Switzerland – November 4, 2024 InSphero, the pioneer in 3D cell culture and organ-on-chip technologies, today announced its distribution partnership with Chayon, a leading Seoul-based laboratory supplies provider. This partnership will bring InSphero’s reliable and scalable 3D in vitro solutions for drug development to South Korean researchers, further expanding the company’s global...

News 04.11.2024 Schlieren / Zurich, Switzerland, 4 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that Frits van Alphen, MD has been appointed as Chief Development Officer (CDO). He succeeds Dr. Gerald P. Parzmair, who stepped...

News 01.11.2024 Schlieren / Zurich, Switzerland, 1 November, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, announces today that the last patient has been enrolled in its 22-site U.S. Phase II trial for its BK polyomavirus (“BKV”)-neutralizing antibody, potravitug. With...

News 01.11.2024 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced...